Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. lessened its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 45.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 44,137 shares of the company’s stock after selling 36,396 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.10% of Pacira BioSciences worth $832,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Wealthfront Advisers LLC purchased a new stake in Pacira BioSciences during the fourth quarter valued at about $1,001,000. AlphaQuest LLC grew its position in Pacira BioSciences by 43.4% during the fourth quarter. AlphaQuest LLC now owns 13,493 shares of the company’s stock valued at $254,000 after acquiring an additional 4,083 shares during the period. Amundi grew its position in Pacira BioSciences by 200.8% during the fourth quarter. Amundi now owns 23,114 shares of the company’s stock valued at $429,000 after acquiring an additional 15,431 shares during the period. PNC Financial Services Group Inc. grew its position in Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after acquiring an additional 513 shares during the period. Finally, Banco Santander S.A. grew its position in Pacira BioSciences by 5.8% during the fourth quarter. Banco Santander S.A. now owns 126,900 shares of the company’s stock valued at $2,391,000 after acquiring an additional 6,900 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PCRX. Barclays boosted their price target on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Needham & Company LLC upped their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. HC Wainwright upped their target price on Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and upped their target price for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $27.22.

Pacira BioSciences Trading Up 1.3 %

Shares of PCRX opened at $24.14 on Friday. The company has a market capitalization of $1.12 billion, a P/E ratio of -11.89 and a beta of 0.86. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $31.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock has a 50-day moving average price of $24.44 and a 200 day moving average price of $19.55.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.